Related Experiment Video
Updated: Jun 3, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
From Escalate to Elevate: A New Paradigm for Comprehensive Cardiogenic Shock Management
Darshan H Brahmbhatt1, Sanjog Kalra2, Adriana Luk2
1Division of Cardiology, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada; Ted Rogers Centre for Heart Research, University Health Network, Toronto, Ontario, Canada; Division of Cardiology, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
Insights
This review discusses current treatments for cardiogenic shock (CS), a condition of low cardiac output (CO). It proposes a novel, immediate treatment approach to rapidly reverse shock and improve patient outcomes.
Area of Science:
- Cardiology
- Critical Care Medicine
- Hemodynamics
Background:
- Cardiogenic shock (CS) is a critical condition characterized by low cardiac output (CO) and end-organ dysfunction.
- Patient prognosis in CS is strongly linked to shock severity, necessitating intensive resource management.
- Current CS treatment relies on a reactive, feedback-based approach, leading to delays in intervention.
Purpose of the Study:
- To review current treatment paradigms for cardiogenic shock (CS).
- To introduce a novel, proactive treatment strategy for rapid amelioration of the shock state.
- To suggest new performance metrics for evaluating CS interventions.
Main Methods:
- Literature review of existing cardiogenic shock (CS) treatment strategies.
- Conceptualization of a novel, immediate intervention approach for CS.
- Proposal of new metrics for assessing treatment efficacy in CS.
Main Results:
- Current CS treatment methods involve incremental adjustments, potentially prolonging the shock state.
- A novel approach emphasizes immediate, decisive interventions to rapidly reverse CS.
- The proposed strategy aims to "break" the shock spiral more efficiently.
Conclusions:
- The standard CS treatment's feedback mechanism can cause critical delays.
- A proactive, immediate treatment strategy may offer superior outcomes in cardiogenic shock.
- New performance metrics are needed to evaluate the effectiveness of rapid CS interventions.
Abstract:
Patients with cardiogenic shock (CS) present with critical hemodynamic compromise with low cardiac output (CO) resulting in end-organ dysfunction. Prognosis is closely related to the severity of shock, and treatment of patients with CS is resource intensive. In this review, we consider the current treatment paradigms alongside the evidence that underpins them. The current standard of treatment relies on a feedback mechanism, where small changes in treatment are assessed to see if clinical improvement occurs. This leads to delays that increase time in the shock state. The novel approach described proposes immediate treatment to ameliorate the shock state to "break" the shock spiral as quickly and decisively as possible, suggesting new metrics to measure performance.
Related Concept Videos
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pathophysiology of Heart Failure
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Heart Failure Drugs: Inotropic Agents
Pathophysiology of Cardiac Performance

